FDA approves the SynCardia Total Artificial Heart for destination study

February 5th, 2015

SynCardia Systems Inc., Tucson, Ariz., has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total Artificial Heart for permanent use, also called destination therapy. The FDA approved the SynCardia Investigational Device Exemption (IDE) application in December to conduct the study in 19 patients […]

Read More